Personalised mRNA cancer vaccines are one of the most exciting breakthroughs to emerge after the COVID-19 pandemic. Using the same mRNA technology, these vaccines are designed to train the immune system to recognise and attack a patient’s unique cancer cells. Although still under clinical evaluation, they have the potential to transform cancer treatment through a more precise and personalised approach.
Key Takeaways
- A cancer vaccine can be preventive or therapeutic. Preventive vaccines reduce the risk of certain cancers, while therapeutic vaccines help the immune system fight existing cancer.
- If you are wondering if there is a vaccine for cancer, the answer is yes, but personalised mRNA vaccines are still undergoing clinical trials for most cancer types.
- Current evidence suggests that personalised anti cancer vaccine therapies may improve outcomes when combined with immunotherapy, particularly in cancers such as melanoma.
- Although cancer vaccines in India currently include preventive vaccines like HPV and Hepatitis B vaccines, personalised mRNA cancer vaccines are not yet part of routine clinical practice.
- Early studies indicate that cancer vaccine side effects are generally mild and manageable, making this an exciting area of research in precision oncology.
The COVID-19 pandemic introduced the world to messenger RNA (mRNA) vaccines, demonstrating how rapidly this technology could be developed to train the immune system against infectious diseases. But while mRNA vaccines gained global attention during the pandemic, scientists had been researching this technology for decades, particularly in cancer treatment.
For many patients, this raises important questions: Is there any vaccine for cancer? Can a cancer cure vaccine eliminate cancer completely? Are these vaccines already available as a cancer vaccine in India? What are the possible cancer vaccine side effects?
As a medical oncologist, I believe it is important to separate scientific breakthroughs from unrealistic expectations. Personalised mRNA vaccines represent one of the most promising advances in precision oncology, but they are still being evaluated in clinical trials for many cancers. Understanding where this technology stands today helps patients make informed decisions about emerging treatment options.
What Are Cancer Vaccines?
One of the most common questions patients ask is, what are cancer vaccines?
Unlike vaccines that protect against infections such as influenza or COVID-19, a cancer vaccine is designed to stimulate the body’s immune system to recognise and attack cancer cells.
Broadly, vaccines and cancer fall into two categories:
- Preventive cancer vaccines
- Therapeutic cancer vaccines
Preventive vaccines reduce the risk of developing certain cancers caused by infections, while therapeutic vaccines are intended to treat existing cancers by enhancing the body’s immune response against tumour cells.
Is There Any Vaccine for Cancer?
The answer is yes, but it depends on the type of vaccine.
Currently, there are two major categories:
1. Preventive Cancer Vaccines
These vaccines help prevent cancers linked to viral infections.
Examples include:
- The HPV vaccine, which helps prevent cervical, anal, vulvar, vaginal, penile, and certain throat cancers.
- The hepatitis B vaccine, which reduces the risk of liver cancer.
These are considered cancer prevention vaccine strategies because they prevent infections that can eventually lead to cancer.
2. Therapeutic Cancer Vaccines
These vaccines are given after cancer has already developed.
Rather than preventing cancer, they help the immune system recognise tumour cells and destroy them. Personalised mRNA vaccines belong to this category and represent the next generation of anti cancer vaccine research.
What is a Personalised mRNA Cancer Vaccine?
A personalised cancer vaccine is created specifically for an individual patient. Instead of targeting a virus, scientists first analyse the patient’s tumour using advanced genomic sequencing.
This allows them to identify unique proteins, called neoantigens, that exist only on that person’s cancer cells. Researchers then develop an mRNA vaccine containing instructions for producing these neoantigens.
Once injected, the vaccine teaches the immune system to recognise these abnormal proteins and mount a targeted immune response against the tumour. Unlike chemotherapy, which affects both healthy and cancerous cells, personalised mRNA vaccines are designed to generate a highly specific immune attack against cancer cells.
This precision is one of the reasons personalised anti cancer vaccine technology is generating enormous interest worldwide.
How Did COVID Accelerate Cancer Vaccine Research?
Although mRNA technology was not invented during the COVID-19 pandemic, the global response dramatically accelerated its development.
The pandemic demonstrated that scientists could:
- Design mRNA vaccines rapidly.
- Manufacture them at scale.
- Deliver them safely to millions of people.
- Generate strong immune responses.
These advances benefited oncology research in several ways.
Researchers now have improved manufacturing platforms, better delivery systems, a greater understanding of immune activation, and more efficient clinical trial processes.
As a result, personalised cancer vaccine development has progressed much faster than many experts anticipated before 2020.
How Do Personalised Cancer Vaccines Work?
The process is remarkably sophisticated. It generally involves the following steps:
Step 1: Tumour Sequencing
A sample of the patient’s tumour is analysed to identify its unique genetic mutations.
Step 2: Neoantigen Selection
Artificial intelligence and advanced computational tools identify which mutations are most likely to trigger an immune response.
Step 3: Vaccine Manufacturing
Scientists produce an mRNA vaccine containing instructions for those selected tumour-specific proteins.
Step 4: Vaccination
The patient receives the vaccine through an injection.
Step 5: Immune Activation
Immune cells learn to recognise the tumour-specific proteins and begin attacking cancer cells carrying those markers.
Because every tumour is genetically different, every personalised cancer vaccine is unique to the individual patient.
Which Cancers Could Benefit from Personalised mRNA Vaccines?
Researchers are investigating personalised mRNA vaccines across a growing number of cancers.
Current clinical trials include:
- Melanoma
- Lung cancer
- Colorectal cancer
- Pancreatic cancer
- Breast cancer
- Ovarian cancer
- Kidney cancer
- Head and neck cancers
Some of the most encouraging results have been reported in melanoma, where personalised mRNA vaccines are being studied alongside immunotherapy to reduce the risk of cancer recurrence after surgery.
While these findings are promising, more research is needed before these vaccines become part of routine care for all cancer types.
Is the Cancer Vaccine Successful?
Some therapeutic cancer vaccines are already approved for specific cancers. In addition, early clinical trials of personalised mRNA vaccines have shown promising results, particularly when combined with immune checkpoint inhibitors.
For example, studies in melanoma have demonstrated that combining a personalised mRNA vaccine with immunotherapy may reduce the risk of cancer recurrence compared with immunotherapy alone.
However, these vaccines are still being evaluated in larger clinical trials before they become widely available.
For this reason, it is more accurate to say that personalised cancer vaccine technology has shown significant promise rather than claiming it is a universal cure.
Is There a Cancer Vaccine in India?
India already has access to cancer prevention vaccine options, including the HPV vaccine to reduce the risk of cervical and several other HPV-related cancers, as well as the Hepatitis B vaccine, which helps lower the risk of liver cancer.
However, personalised mRNA cancer vaccine therapies are still in the research and clinical trial phase worldwide. While Indian researchers and biotechnology companies are actively exploring cancer vaccine technologies, personalised mRNA vaccines have not yet become part of routine clinical practice in India.
As global clinical trials continue to report encouraging results, it is expected that these therapies may eventually become available to a broader patient population, subject to regulatory approvals and further evidence demonstrating their safety and effectiveness.
Can a Cancer Cure Vaccine Eliminate Cancer Completely?
The phrase cancer cure vaccine often creates unrealistic expectations.
At present, there is no vaccine that can completely cure every type of cancer.
Instead, personalised anti cancer vaccine therapies are designed to strengthen the body’s immune system so it can better recognise and destroy cancer cells.
Depending on the type and stage of cancer, these vaccines may help:
- Reduce the risk of cancer returning after surgery
- Improve the effectiveness of immunotherapy
- Delay disease progression
- Generate long-lasting immune memory against tumour cells
Like chemotherapy, targeted therapy, and immunotherapy, cancer vaccines are expected to become one component of a comprehensive treatment plan rather than a standalone cure.
The future of oncology lies in combining multiple treatment approaches to achieve the best possible outcomes for each patient.
What Are the Possible Cancer Vaccine Side Effects?
Like all medical treatments, personalised cancer vaccines can cause side effects. Fortunately, early clinical trials suggest that most cancer vaccine side effects are mild to moderate and result from activation of the immune system.
Common side effects include:
- Pain or redness at the injection site
- Mild fever
- Fatigue
- Chills
- Headache
- Muscle aches
These symptoms are generally temporary and resolve within a few days.
Serious complications appear to be uncommon in current clinical studies, although researchers continue to monitor long-term safety as larger trials progress.
When personalised vaccines are combined with immunotherapy, patients may also experience immune-related side effects associated with checkpoint inhibitors. These vary depending on the treatment regimen and should always be discussed with the treating oncologist.
Overall, the safety profile of personalised mRNA anti cancer vaccine therapies has been encouraging, but ongoing research is essential to better understand their long-term effects.
What Challenges Still Need to Be Overcome?
Despite the excitement surrounding personalised cancer vaccine research, several challenges remain before these therapies become widely available.
Some of the biggest hurdles include:
Manufacturing Time
Because every vaccine is created specifically for one patient, designing and producing each personalised vaccine takes time.
Cost
Advanced genomic sequencing and customised manufacturing make personalised vaccines more expensive than conventional treatments.
Tumour Diversity
Cancer cells constantly evolve. Some tumours may develop new mutations that allow them to escape immune recognition, making treatment more challenging.
Identifying the Right Patients
Not every patient or cancer type responds equally well to immunotherapy or personalised vaccines. Researchers are working to identify biomarkers that predict who is most likely to benefit.
Despite these challenges, rapid advances in genomic sequencing, artificial intelligence, and mRNA manufacturing continue to improve the feasibility of personalised cancer vaccines.
What Does the Future Hold for Vaccines and Cancer?
The relationship between vaccines and cancer is entering an exciting new era. The goal is to create highly personalised treatment strategies that not only eliminate existing cancer cells but also train the immune system to prevent recurrence.
Several ongoing international Phase III clinical trials are expected to provide stronger evidence over the next few years, potentially bringing personalised cancer vaccine therapies closer to routine clinical practice.
While many questions remain, the progress made since the COVID-19 pandemic has significantly accelerated research in this field, offering renewed hope for patients with difficult-to-treat cancers.
Frequently Asked Questions
1. What are cancer vaccines?
They are vaccines designed either to prevent certain cancers caused by infections or to help the immune system recognise and attack existing cancer cells.
2. Is there any vaccine for cancer?
Yes. Preventive vaccines such as the HPV and Hepatitis B vaccines are already available, while personalised therapeutic cancer vaccine approaches are currently being evaluated in clinical trials.
3. Is a cancer vaccine successful?
Results have been encouraging. Early studies suggest that personalised mRNA vaccines can improve immune responses and reduce the risk of recurrence in selected cancers when used alongside immunotherapy. However, research is still ongoing before widespread clinical adoption.
4. What are the cancer vaccine side effects?
Most reported cancer vaccine side effects include mild fever, fatigue, headache, muscle aches, and soreness at the injection site. Serious side effects remain uncommon in current clinical trials.
5. Will personalised cancer vaccines become available in India?
Research into cancer vaccines in India is progressing, but personalised mRNA cancer vaccines are not yet part of routine clinical practice. As international clinical trials continue and regulatory approvals evolve, these innovative treatments may become available in the future.